search
Front > News

Teva teams with Sanofi on inflammatory bowel treatment

Richard Francis credit: PR
Richard Francis credit: PR
4 Oct, 2023 11:38
שלח תגובה במיילGlobes correspondent

Under the terms of the collaboration agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones.

Israeli drug developer Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) and French pharmaceutical company Sanofi (Nasdaq: SNY; Euronext: SAN) have today announced a collaboration to develop and commercialize TEV 574, currently in Phase 2b clinical trials, for the treatment of ulcerative colitis and Crohn's Disease, two types of inflammatory bowel disease.

Under the terms of the collaboration agreement, Teva will receive an upfront payment of $500 million and up to $1 billion in development and launch milestones. Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement and Sanofi will lead the development of the Phase 3 program.

Teva will lead commercialization of the product in Europe, Israel and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia and the rest of the world. The deal will become effective after customary closing conditions are met. Initial program results are expected to be available in 2024.

An estimated 10 million people worldwide live with inflammatory bowel disease.

Teva president and CEO Richard Francis said, "This is a new era for Teva, and our robust, innovative pipeline is key to our Pivot to Growth strategy. This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A. We are honored to partner with Sanofi to bring their proven capabilities, leadership, and success in the immunology and gastroenterology space together with our capabilities to optimize development and global launches."

Sanofi CEO Paul Hudson added, "Anti-TL1As are a promising class of therapies, and we believe that TEV ‘574 could emerge as a best-in-class option for people living with serious gastrointestinal diseases. This collaboration strengthens our commitment to advancing innovative treatment options for inflammatory conditions with a high unmet need and bolsters our goal to be an industry leader in immunology."

Published by Globes, Israel business news - en.globes.co.il - on October 4, 2023.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2023.

Richard Francis credit: PR
Richard Francis credit: PR
Hearst Tower New York credit: Shutterstock Hearst Ventures shuts down Israel office

The closure is part of a global move to shut down offices outside the US, but the fund will continue investment in Israeli companies.

US President Donald Trump credit: Shutterstock US reciprocal procurement demands put Israel in a bind

Reciprocal procurement on major tenders injects billions of dollars into Israel every year and supports hundreds of local companies but Israel may need to relax them in exchange for US tariff cuts.

Israeli stocks on Wall Street credit Nasdaq, Raanan Tal, Itay Tagar, Space Cut design: Tali Bogdanovsky Despite turmoil, analysts bullish on Israel Wall Street stocks

After recent strong declines, analysts are tipping Israeli tech stocks, with relative immunity to recession and limited exposure to tariffs.

Intel's 2025 vision credit: Intel Will Intel's sell-off include Israeli assets?

After the sale of Altera, "Globes" considers whether the troubled chipmaker will sell Mobileye or its Kiryat Gat fab.

CloudShare management team credit: PR Bow River Capital buys Israeli co CloudShare

The Denver-based alternative asset manager is paying an estimated $60-80 million for the SaaS provider of AI guided solutions for complex technical training requirements.

Housing prices continue to rise credit: Tali Bogdanovsky Israel's housing price rise riddle

Despite a huge inventory of unsold new homes in central Israel and weak sales, apartment prices are still rising. "Globes" analyzes the data.

Inflation credit: Tali Bogdanovsky March CPI higher than expected, housing prices rise

The March reading brings annual inflation in Israel down to 3.3% from 3.4% at the end of February.

Ben Gurion airport credit: Tali Bogdanovsky Abundance of affordable last minute Passover flight deals

The return of foreign airlines to Israel has brought down fares dramatically even for last minute vacations.

Karish rig credit: Eyal Izhar Kesem Energy signs gas deals worth $2.8b

The power plant, scheduled to begin operating in 2029, will buy gas worth $2 billion from Energean and a further $700-800 million from the Tamar partners.

Kosher for Passover Coca Cola bottles credit: social media Why are yellow cap Coca Cola bottles different from all others?

Nostalgic Coca Cola aficionados claim that the kosher for Passover version, made from sugar cane instead of high fructose corn syrup, is the genuine taste of the soft drink.

Avigdor Willenz credit: Intel Exclusive: Avigdor Willenz's Element Labs raises $50m

The Israeli startup is developing AI processors for inference, the stage in which AI models are activated after they have already been trained.

Ilya Sutskever credit: Cadya Levy SSI hiring dozens in Israel

AI company Safe Superintelligence is hiring many dozens of people in Tel Aviv, "Globes" has learned.

Johny Srouji credit: Amos Ben Gershom GPO Apple SVP leads senior delegation of execs to Israel

Jony Srouji: I am always filled with renewed energy and optimism about our shared achievements when I visit our R&D centers here.

Israeli apartments Credit: Shutterstock Apartments sold and rented

A selection of recent real estate deals in Israel in Tel Aviv, Ramat Gan, Petah Tikva, Givat Shmuel, Tiberias and Dimona.

Infinity Tower Tel Aviv credit: Courtesy Hagag Group French investors buy 2 Tel Aviv apartments for NIS 27.5m

The two apartments are in Hagag Group's Infinity Tower in the Summeil district.

El Al plane credit: Shutterstock El Al receives state approval to distribute dividend

The Israeli airline has now announced that it will be able to distribute up to 30% of net profit in 2025 and up to 40% in 2026-2028.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018